We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia (CMMoL) after allografting. Of the 26 patients (median age 62 years, range 28-75) with relapsed AML (n ¼ 24) or CMMoL (n ¼ 2), 11 (42%) had poor-risk cytogenetics. Twenty-three patients had received fludarabinebased reduced-toxicity conditioning regimens, and three had received conventional myeloablative conditioning. Patients received 5-azacytidine s.c., at a total daily dose of 100 mg, on days 1-3, to be followed by DLI on day 10, with the next course of treatment to be started on day 22. A total of 60 courses of 5-azacytidine were administered, with a median of 2 courses (range: 1-10). In 44 courses, 5-azacytidine was followed by DLI, and thus 19/26 (73%) patients received at least one course of this combined treatment. Clinically relevant neutropenic infections not associated with progressive disease developed in four patients, one of them succumbing to sepsis. Only two patients developed de novo acute GvHD after the combination of 5-azacytidine and DLI. Overall, 66% of the patients benefited from this treatment, with continued CRs achieved in 4 (16%) patients, lasting a median of 525 days (range: 450 þ to 820 þ ), and a 50% rate of temporary disease control with stable mixed chimerism (median duration 72 days). The median survival from the start of 5-azacytidine treatment was 136 days (range: 23 to 873 þ ), with an estimated 2-year survival probability of 16%. In conclusion, this non-intensive outpatient regimen of 5-azacytidine followed by DLI is feasible, with a very low aGVHD rate. Objective responses, including continuous complete donor chimerism, occurred also in patients with poor-risk cytogenetics.
Introduction
The epigenotype of myeloid leukemic blasts, as for other neoplasias, is marked by large sets of genes being heavily repressed through DNA methylation and inactivating histone modifications. These include tumor suppressor genes, antiapoptotic and cell-cycle regulatory genes, as well as cancer testis Ags. 1, 2 Pharmacological gene reactivation has provided a strong rationale for developing treatment approaches in leukemia and myelodysplastic syndromes (MDSs) using hypomethylating agents, which revert the aberrant DNA hypermethylation, and histone deacetylase inhibitors that antagonize promoter silencing. Although hypomethylating agents have shown very interesting activity in large phase II and III clinical trials of MDS, 3, 4 different venues for combining these drugs with other therapeutic principles in leukemia and MDS are underway. Among these, the use of epigenetic drugs in the context of adoptive T-cell transfer is particularly interesting. It is based on the discovery by Pinto et al. 5 of HLA upregulation by the DNA demethylating agent decitabine in myeloid leukemic blasts and the in vivo observation of upregulation by decitabine of cancer testis Ags such as NY-ESO-1 and a number of MAGE genes. 6 On the basis of these results, it is rational to render malignant cells more immunogenic toward T-cell killing by pretreatment with low doses of a hypomethylating agent, which is not intended to exert a primarily cytotoxic effect.
A favored therapeutic option for patients with AML and MDS relapsing after allogeneic blood SCT is donor lymphocyte infusions (DLIs), 7 as first described by Kolb et al., 8 followed by a second transplant when feasible, 9, 10 which in older patients is often not the case. However, the rates of anti-leukemic response and complete donor chimerism range between 30-40 and o10%, respectively. 11, 12 Measures to enhance the therapeutic index of DLI by the addition of IL-2 13 or low-dose cytarabine (LD-AraC) combined with GM-CSF 14 have not shown a consistent improvement. To use the particular mechanisms of action of DNA demethylating agents within the transplant setting, decitabine had been incorporated into the treatment of patients before allografting 15, 16 and 5-azacytidine treatment followed by DLI has recently been described for a patient relapsed after allografting for MDS. 17 However, the optimal dose of a hypomethylating agent in this setting, where hematopoiesis may be much more sensitive to the myelotoxicity mediated sometimes by even low doses of the drugs, has not yet been established.
On the basis of promising activity of a 3-day schedule of decitabine, 4 and the effectiveness of a 3-day schedule of low-dose 5-azacytidine in reinducing fetal hemoglobin, 18 we have embarked on a sequential treatment of AML/highrisk MDS patients with 5-azacytidine given for 3 days followed by DLI. This treatment showed promising feasibility, with a very low GVHD rate, and clinical benefit in 66% of the patients, including attainment of continued CR in four patients in whom previous DLI alone (median of 4 infusions, range 2-6) had not been sufficient for disease control.
Patients, materials and methods

Patients
Between October 2006 and August 2008, hematological relapse after allogeneic transplantation was diagnosed in 45 patients with AML or MDS. Of these, 26 received 5-azacytidine (14 already having received DLI), to be followed by DLI. Inclusion criteria for this treatment were relapsed disease (AML, MDS) after allografting, no prohibitive GVHD, informed written consent to this treatment and no option of imminent allografting. The remaining 19 patients did not receive this treatment either because of response to DLI, the option of immediate next allografting, because of leukemic relapse necessitating immediate institution of chemotherapy (usually high-dose AraC/mitoxantrone), a low performance status and/or infectious complications.
Treatment
One treatment course (duration 21 days) consisted of lowdose 5-azacytidine (100 mg total dose per day, without dose adaptation to body surface) s.c. on 3 consecutive days (with a total dose of 300 mg per course) on days 1-3, followed by DLI on day 10. When the mixed chimerism in the peripheral blood remained stable at evaluation of the first course of treatment, without evidence of increasing leukocytosis or undue toxicity, a second course of this treatment was started on day 22, also to be repeated 3 weeks later, that is, on day 43 from the start of the first course, and so on. Treatment cycles were thus continued until attainment of CR or treatment failure. Dose escalations of 5-azacytidine (with the goal of response improvement) to 125 and 150 mg per day Â 3 days were carried out in a limited number of patients. All episodes of infectious and other complications necessitating readmission to the hospital during the treatment period were captured. Neutropenia was scored according to the Common Toxicity Criteria (CTC, v 3.0).
Response criteria and evaluation
Relapse after transplantation (the inclusion criteria for treatment with 5-azacytidine) was defined as 45% blasts in the BM and detection of mixed chimerism. Responses to 5-azacytidine were evaluated by BM studies scheduled 6 weeks after the first administration, with earlier BM studies performed in case of suspected progressive disease. A CR was defined as o5% blasts in a BM of adequate cellularity and no Auer rods, absence of leukemic blasts in the peripheral blood, an ANC of X1000/ml, plts of X100 000/ml and transfusion independence. 19 Patients not fulfilling CR criteria were scored as having achieved temporary disease control when the mixed chimerism in the peripheral blood remained stable, without evidence of increasing leukocytosis, for at least 4 weeks (chimerism was routinely monitored every 1-2 weeks in the peripheral blood). When no temporary disease control was achieved, the patient was scored as a treatment failure.
Chimerism and Flt-3 mutational status analyses Quantification of chimerism was carried out on marrow and/or peripheral blood samples by FISH or by a variable number of tandem repeat studies as described earlier. 20 Flt-3 mutational status was determined in 11 patients (6 with normal karyotype, 4 with chromosomal abnormalities and 1 where no metaphases were obtained) using BM and/or peripheral blood blast cells as described. 21 
Statistical methods
Median and 2-year survival were calculated from the first day of 5-azacytidine treatment, by using the Kaplan-Meier method. Differences in OS were studied by univariate analyses applying log-rank tests on the following pretreatment variables: age (o60 vs X60 years), leukocyte count (o5000 vs X5000/ml), peripheral blood blasts (o1 vs X1%), BM blasts (o20 vs X20%), cytogenetic risk (favorable or intermediate vs adverse), time from allografting to relapse (o36 vs X36 weeks), DLI before the first dose of 5-azacytidine and the donor type (related vs unrelated). A significance level of 5% was chosen without adjustment for multiple testing. All calculations were performed using SPSS (version 16.0).
Results
Patient characteristics and treatment
Between October 2006 and August 2008, 26 patients with a median age of 62 years (range 28-75), who had relapsed after allografting (24 with AML, 2 with proliferative chronic myelomonocytic leukemia, IPSS high-risk), were included. Detailed patient characteristics are given in Table 1 . Patients received low-dose 5-azacytidine on days 1-3, to be followed on day 10 by DLI, with the next treatment course of 5-azacytidine to be started at day 22, that is, within a 3-week cycle. Where feasible, the second and subsequent courses also contained at least one DLI to . As only 4 of the planned 7 doses could be administered because of ensuing neutropenia (resulting in a total dose of 300 mg/m 2 5-azacytidine administered during the first treatment course), he and subsequent patients received an even lower 5-azacytidine dose of 300 mg total dose per course. This dose was divided into three doses of 100 mg 5-azacytidine, given on 3 consecutive days. Patients received a median of two courses (range 1-10), and a total of 60 courses of 5-azacytidine were administered, in 44 (73%) courses followed by DLI (Table 2) .
Dose escalations of 5-azacytidine (to 375 and 450 mg per course) were performed in four patients in a total of 16 courses (125 mg per day in 14 courses, 150 mg per day in two courses). In particular, in three patients tolerating the continued treatment at the starting dose level very well but not converting to complete donor chimerism, increased dosing was initiated at the third (n ¼ 2) and fourth (n ¼ 1) courses, without undue hematological toxicity; one patient with an extramedullary relapse of AML received a starting dose of 125 mg 5-azacytidine per day. In two patients, leukocytosis of 450.000/ml during course 1 of 5-azacytidine/DLI necessitated additional cytoreduction, which was achieved by the administration of hydroxyurea.
Toxicities
Of the 26 patients, 8 had to be readmitted at least once to the hospital because of infectious complications, necessitating a total of 10 hospitalizations, 9 of which were associated with grade III/IV neutropenia, 4 with progression of the disease. These admissions occurred during treatment course 1 in six patients, during course 2 in one patient, during course 4 in two patients and during course 8 in one patient. Treatment continuation with 5-azacytidine was feasible after 5 of 10 infectious complications, but had to be terminated after the other 5 episodes, mostly because of progressive disease. In a single patient, the neutropeniaassociated complication was fatal (urosepsis with Entero- Table 2 Feasibility 
Responses and survival
Response to the treatment is given in Table 3 : 4 of 26 (16%) patients achieved a complete and lasting hematological response, in three of them with conversion to complete chimerism (duration 17 þ , 25þ and 29 þ months, respectively, from the start of 5-azacytidine). One additional responder (duration 20 þ months) had persistence of mixed chimerism despite normalization of peripheral blood counts and blast clearance in the BM, most likely representing so-called 'split chimerism'. 22 Thirteen (50%) patients attained temporary disease control (mixed chimerism, stable leukocyte counts) over a median of 72 days (range 37-238). In the remaining nine patients, no disease control was achieved. Of 26 patients, 5 are alive at the time of this report. Seven patients received a second transplant after 5-azacytidine/DLI treatment. The median survival of all patients from the start of 5-azacytidine was 136 days, with an estimated 2-year survival of 16% (Figure 1) .
Univariate analyses of eight pretreatment variables on survival (21 events) are shown in Table 4 . Survival was significantly longer in patients with o1% blasts in the peripheral blood (P ¼ 0.003), those with longer remission duration after allogeneic transplantation (P ¼ 0.013) and in those having received DLI treatment before the initiation of 5-azacytidine relapse treatment (P ¼ 0.042), whereas leukocyte count, BM blast percentage, cytogenetics, donor type and patient age were not statistically significant parameters for differences in OS. Performing a multivariate analysis yielding robust results was not feasible (data not shown), as for eight pretreatment parameters the number of events (21 deaths) was far too small.
Discussion
Immunotherapy of relapsed AML/MDS after allogeneic blood SCT by stopping of the immunosuppression and administration of DLI is a standard of care. 11, 12 Attempts to raise the therapeutic index of DLI by chemotherapy with high-dose cytarabine, 23 IL-2 administration, 13 a combination of low-dose (LD) AraC and GM-CSF 14 or ex vivo activated DLI 24 have not resulted in consistently enhanced DLI activity. Hypomethylating cytosine analogs offer an interesting alternative to low-dose AraC in this setting. Response criteria are given in the section Patients, materials and methods. a Three of the four patients attaining CR also had continued complete donor chimerism, in one of them (AML and sole deletion 5q) maintained with lenalidomide, in the fourth patient, the initial chromosomal abnormality of monosomy 7 was not detectable during long-term disease control despite continued mixed donor chimerism, indicative of split chimerism. 5-azacytidine and DLI after allografting M Lübbert et al Particular activity of both decitabine and 5-azacytidine in MDS patients with poor cytogenetics has been noted in phase II and III studies. 3, 25 One of the mechanisms of action of 5-azacytidine, and the one most prominently studied, is DNA demethylating activity, offering a strong rationale as gene reactivation may result in immunomodulatory effects in vivo. This effect would be unique to drugs with epigenetic activity, as LD-AraC has no DNA methyltransferase inhibitor activity 26 and, when compared with DNA demethylating agents, does not reinduce genes. 27 In an attempt to improve the outcome of AML/MDS patients eligible for DLI, pretreatment with 5-azacytidine was initiated at a total dose per course of 300 mg (which is less than one-third of the FDA-approved dose of 525 mg/m 2 per treatment course), and, with a 3-day schedule, less than half of the 7-day drug exposure time of that schedule. The rationale for administering DLI 10 days after the first dose of 5-azacytidine in a given treatment cycle was to allow for maximum induction of cancer testis Ag expression, based on in vitro data showing a time-dependent upregulation of these proteins until at least day 6, with subsequent decrease at day 21. 28 Given the known half-life of the drug, it appeared very safe to allow for a 7-day washout period between the last injection of 5-azacytidine and the administration of DLI, so as to not compromise the infused immune cells.
Even with this low dose of 5-azacytidine combined with DLI, continued CR was obtained in 4 patients (all of them pretreated with DLI), and clinically meaningful disease control was achieved in 13 additional patients. In a prospective study, correlative efforts should be aimed at the investigation of in vivo de-repression of cancer testis Ags on the malignant cells purified by CD34 selection, so as to ask whether this in vivo immunomodulatory effect may serve as a surrogate parameter for response.
A combination of 5-azacytidine and DLI is based on the rationale that DNA hypomethylating agents may de-repress HLA molecules and cancer testis Ags on the leukemic blasts, rendering them more sensitive to the antileukemic activity of DLI in the process. Of course, the primary mechanism(s) by which the hypomethylating agents mediate their activity in MDS and AML in vivo is a matter of debate, and beyond the in vivo DNA demethylation of several genes, 27, 29, 30 DNA damage has also been shown. [31] [32] [33] Although at least part of the activity of 5-azacytidine in the setting may be a 'debulking' effect on the leukemic population, it is notable in this context that no treatment-related leukopenia was seen in two of the patients attaining CR subsequent to repeated courses of 5-azacytidine and DLI. This observation argues against a solely cytotoxic effect of the drug. BM studies performed earlier during treatment evaluation, for example, at day 14, will be necessary to monitor more closely the in vivo effects of this treatment.
In univariate analyses of eight pretreatment parameters, peripheral blood blasts o1%, an interval of X36 weeks from transplant to relapse, and earlier DLI treatment were significantly associated with longer survival. The absence of blasts in the peripheral blood is a well-known predictor for better outcome after allografting, as is the longer CR duration. Pretreatment with DLI before 5-azacytidine (borderline significance in this analysis) may reflect slower kinetics of the relapse, or a delayed effect of the DLIs already infused at the time of 5-azacytidine start. It is noted that older patient age, unrelated donor stem cell source and poor-risk cytogenetics were not predictive for significantly shorter OS. The latter is in accordance with large and growing data sets indicating that patients with poor-risk cytogenetics also respond to hypomethylating agents (see above), which is in striking contrast to the very poor response of these patients to low-dose Ara-C.
The triggering of GVHD by the sequence of 5-azacytidine and DLI treatment is a serious theoretical concern, as the DNA demethylating agents could hypothetically upregulate Ags also on normal, bystander tissue such as skin, gut and liver. Thus, the low rate of de novo GVHD in this patient series was very encouraging, arguing against an off-target effect of this hypomethylating agent on normal cells, at least at the dose and schedule given.
In conclusion, these results are supportive of a model in which the effect of active immunotherapy can be boosted by an epigenetically active drug, using a low-dose 5-azacytidine schedule with good feasibility and an encouraging therapeutic index, with a low rate of de novo GVHD. A better understanding of the mechanism of action of this response is an area of active research.
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